Journal article
Update on emerging drugs for sarcopenia - Age-related muscle wasting
GS Lynch
Expert Opinion on Emerging Drugs | Published : 2008
Abstract
Sarcopenia - the progressive loss of muscle mass with advancing age is characterised by a deterioration of muscle quantity and quality leading to a gradual slowing of movement and a decline in strength and power. Sarcopenia is a highly significant public health problem. Frail elders often require assistance for accomplishing even basic tasks of independent living, and they are also at increased risk of serious injury from sudden falls and subsequent fractures. Since these age-related changes are largely attributed to the complex interaction of factors affecting neuromuscular transmission, muscle architecture, fibre composition, excitation-contraction coupling, and metabolism, the mechanisms ..
View full abstractRelated Projects (6)
Grants
Awarded by Australian Research Council Discovery
Awarded by National Health and Medical Research Council of Australia
Awarded by Muscular Dystrophy Association (USA)
Awarded by Australian Research Council
Funding Acknowledgements
The author is grateful for research grant support from the Australian Research Council Discovery-Project funding scheme (DP0665071, DP0772781), National Health and Medical Research Council of Australia (454561, 509313, 566818, 566820), Muscular Dystrophy Association (USA, 4167), Association Francaise contre les Myopathies, Pfizer, Inc. (USA), E Hoffmann-La Roche Ltd. (Switzerland) and Merck & Co., Inc. (USA).